Featured Spotlight
Eli Lilly’s Weight-Loss Drug Demand Is Nearly Limitless
Eli Lilly opened Wednesday’s session with a blowout second-quarter earnings report, sending shares sharply higher and cementing the drugmaker’s position as a market leader.
